| Study |
Age at enrolment |
Follow up |
Age at completion of primary series |
Setting |
No. of participants |
PCV serotypes |
| Black 2002a |
2 months |
Earliest of the following dates: onset of first invasive disease, death, end of trial |
12 months |
Northern California Kaiser Permanente (NCKP) |
37,868 |
4, 6B, 9V, 14, 18C, 19F, 23F |
| Cutts 2005 |
6‐51 weeks |
Earliest of the following dates: first episode of the relevant endpoint, withdrawal, death, age 30 months, end of follow‐up on April 30, 2004 |
6 months |
The Gambia |
17,437 |
1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F |
| Lucero 2009 |
6 weeks‐ < 6 months |
Earliest of the following dates: 24 months of age, end of follow‐up on December 31, 2004 |
6 months |
Philippines |
12,191 |
1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F |
| Madhi 2005a (HIV‐1 negative children only) |
28‐84 days old |
60‐1354 days after enrolment |
9 months |
Soweto, South Africa |
37,259 |
1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F |
